NCT03864627View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 25, 2019

Primary Completion Date

February 27, 2020

Study Completion Date

February 27, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

MOR106

MOR106 liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).

DRUG

Placebo

Placebo liquid formulation for s.c. injection administered concomitantly with TCS (medium potency).

Trial Locations (14)

10012

Greenwich Village Dermatology, New York

33021

Encore Medical Research, Hollywood

33030

Advanced Research Institute of Miami LLC, Homestead

33185

Vista Health Research, Miami

40241

DS Research, Louisville

46250

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

60008

Arlington Dermatology, Rolling Meadows

77004

Center for Clinical Studies, Houston

77598

Center for Clinical Studies, Webster

78229

Progressive Clinical Research, San Antonio

90057

LA Universal Research Center, Inc., Los Angeles

92103

MedDerm Associates, San Diego

92647

Marvel Research, LLC, Huntington Beach

92708

First OC Dermatology, Fountain Valley

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT03864627 - A Study to Evaluate the Safety and Tolerability of MOR106 Administered Concomitantly With Topical Corticosteroids, in Adult Participants With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter